Is soluble transferrin receptor a good marker of iron deficiency anemia in chronic kidney disease patients?

Gupta, Samta; Uppal, Beena; Pawar, Basant

doi:10.4103/0971-4065.57105

Cited by 22 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to that, Hb and HCT levels showed a significant increasing linear trend. In addition, sTfR was significantly correlated with the Hb, HCT, RET%, rhEPO dose, and rate of chalybeate use, indicating that sTfR could be used as a marker of erythropoiesis, which is also consistent with previous studies [17][18][19][20][22][23][24][25]. Only one (TIBC) out of the four iron parameters was negatively correlated with sTfR, indicating that sTfR could not accurately reflect the iron status of HFD patients in our study.…”

Section: Discussionsupporting

confidence: 77%

Soluble transferrin receptor as a marker of erythropoiesis in patients undergoing high-flux hemodialysis

Yin

Song

2017

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Anemia is a common complication in chronic kidney disease (CKD) patients receiving hemodialysis. The effect of high-flux dialysis (HFD) on anemia remains unclear. This prospective study aimed to evaluate the effect of HFD on anemia, and the potential of soluble transferrin receptor (sTfR) as a marker of iron status and erythropoiesis in CKD patients on hemodialysis. Forty patients, who switched from conventional low-flux dialysis to HFD for 12 months, were enrolled in this study. The levels of sTfR, hemoglobin (Hb), iron, and nutritional markers, as well as the dose of recombinant human erythropoietin (rhEPO) and use of chalybeate were determined at 0, 2, 6, and 12 months after starting HFD. HFD significantly increased the hemoglobin level and reduced sTfR level in CKD patients (p < 0.05). In addition, significant decreasing linear trends were observed for rhEPO dosage and chalybeate use (p < 0.05). The level of sTfR was positively correlated with the percentage of reticulocytes (RET%), rhEPO dose, and chalybeate use, while it was negatively correlated with Hb levels and total iron-binding capacity results (all p < 0.05). A univariate generalized estimating equation (GEE) model showed that the Hb level, RET%, rhEPO dose, and chalybeate use were the variables associated with sTfR levels. A multivariate GEE model showed that the time points when hemodialysis was performed were the variables associated significantly with sTfR levels. Overall, our findings suggest that HFD can effectively improve renal anemia in hemodialysis patients, and sTfR could be used as a marker of erythropoiesis in HFD patients.

show abstract

Section: Discussionsupporting

confidence: 77%

Soluble transferrin receptor as a marker of erythropoiesis in patients undergoing high-flux hemodialysis

Yin

Song

2017

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

show abstract

“…Similar findings were observed in a study by Jain et al (2009) 10 conducted in India. In another study by Gupta et al (2009) 11 found that the mean value of serum iron in CKD patients was higher than IDA patients whereas TIBC was lower in CKD patients with higher TSAT values.…”

Section: Discussionmentioning

confidence: 93%

Role of Serum Transferrin Receptor in Diagnosing and Differentiating Iron Deficiency Anemia from Anemia of Chronic Disease in Patients with Chronic Kidney Disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It has been shown that, ferritin values increased in IDA with CKD patients; may be due to chronic inflammatory process. In a study Gupta et al 11 , the serum ferritin was much higher in patients with CKD than in patients with IDA without CKD.…”

Section: Resultsmentioning

confidence: 90%

“…Similar findings were observed in a study by Jain et al 10 conducted in India. In another study by Gupta et al 11 , found that the mean value of serum iron in CKD patients was higher than IDA patients, whereas TIBC was lower in CKD patients with higher TSAT values.…”

Section: Resultsmentioning

confidence: 90%

See 1 more Smart Citation

Serum Soluble Transferrin Receptor-Ferritin Indices in Diagnosing and Differentiating Iron Deficiency Anemia from Anemia of Chronic Disease among Patients with Chronic Kidney Disease

Latif¹,

Hoque²,

Alam³

et al. 2019

Birdem Med J

View full text Add to dashboard Cite

Background: Anemia is common in patients with chronic kidney disease (CKD) and this is generally anemia of chronic disease (ACD), but iron deficiency anemia (IDA) is also common. Soluble transferrin receptor (sTfR) is a useful marker for IDA. Present study was undertaken to assess the utility of sTfR as a marker of IDA and to differentiate ACD from IDA in selected group of Bangladeshi patients with CKD. Methods: This cross-sectional study was conducted in the Department of Nephrology, BSMMU, Dhaka, Bangladesh from January 2013 to December 2014. Patients with anemia admitted in Nephrology Department, whether on hemodialysis or not and Medicine Department of BSMMU were taken for study. The study population was further divided into two groups; Group A, patients (30) who were having IDA and Group B, patients (40) with ACD and a control group was also selected. Data were collected by face to face interview and laboratory investigations with a self-administered questionnaire. Results: The mean age of the patients in Group A and Group B were 38.40±13.23 and 34.85±10.52 years respectively and male-female ratio were 0.5:1 and 1:0.5. Mean sTfR level was higher (4.81± 1.64 μg/ml) in patients with IDA than (2.89±1.40 μg/ml) in patients with ACD (p <0.0001). Mean ferritin level was 599.59± 449.15μg/L in ACD patients whereas 101.23±119.42 in IDA patients (p<0.0001). Total iron binding capacity (TIBC) was more in ACD patients with sTfRe”3μg/ml as compared to ACD patients with sTfR<3μg/ml. Transferrin saturation (TSAT) level was significantly decreased in ACD patients with sTfRe”3μg/ml as compared to ACD patients with sTfR<3μg/ml. sTfR and ferritin indices between group A (IDA) and group B (ACD) shows mean sTfR:logSF level was significantly (P<0.001) high in group A (2.71±1.13) in comparison to group B (1.08±0.54). Mean log sTFR:SF was also significantly higher (P<0.05) in group A (0.001±0.0008) compared to group B (0.013±0.012). Conclusion: sTfR level has a comparable ability to serum ferritin in diagnosing IDA and ACD. However, sTfR and serum ferritin alone cannot definitely exclude coexisting iron deficiency in ACD. Log sTfR/ ferritin index has role in identifying development of iron deficiency in ACD whereas sTfR/ log SF ratio can differentiate pure IDA from ACD with or without iron deficiency. Thus, it is important to estimate both serum sTfR and sTfRferritin indices to be able to differentiate pure IDA, ACD and ACD with co-existing iron deficiency thus providing a non-invasive alternative to bone marrow iron. Birdem Med J 2019; 9(2): 151-156

show abstract

Is soluble transferrin receptor a good marker of iron deficiency anemia in chronic kidney disease patients?

Cited by 22 publications

References 17 publications

Soluble transferrin receptor as a marker of erythropoiesis in patients undergoing high-flux hemodialysis

Soluble transferrin receptor as a marker of erythropoiesis in patients undergoing high-flux hemodialysis

Role of Serum Transferrin Receptor in Diagnosing and Differentiating Iron Deficiency Anemia from Anemia of Chronic Disease in Patients with Chronic Kidney Disease

Serum Soluble Transferrin Receptor-Ferritin Indices in Diagnosing and Differentiating Iron Deficiency Anemia from Anemia of Chronic Disease among Patients with Chronic Kidney Disease

Contact Info

Product

Resources

About